Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Revlimid lenalidomide: Updated Phase III data

Updated data from the Phase III E4A03 trial in 445 patients with newly diagnosed MM showed 2-year survival

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE